Malignant News and Research

RSS

Innovative therapy offers new hope to breast cancer patients

A novel breast-cancer therapy that partially reverses the cancerous state in cultured breast tumor cells and prevents cancer development in mice, could one day provide a new way to treat early stages of the disease without resorting to surgery, chemotherapy or radiation, a multi-institutional team led by researchers from the Wyss Institute of Biologically Inspired Engineering at Harvard University reported January 1 in Science Translational Medicine.

2 Jan 2014

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

27 Dec 2013

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth, UT Southwestern Medical Center researchers report.

27 Dec 2013

Concordia Healthcare acquires Pinnacle Biologics

Concordia Healthcare Corp., an integrated, specialty healthcare company focused on the acquisition of legacy pharmaceutical products and medical devices and the acquisition and/or development of orphan drugs, announced today that it has acquired Pinnacle Biologics, Inc., a U.S.-based biopharmaceutical company specializing in legacy pharmaceuticals which have the potential for development as orphan drugs to treat cancer indications in addition to those for which they have previously been approved.

24 Dec 2013

Manipulating epigenetic mechanism may promote cell death in pediatric brain cancer

Researchers at the Federal University of Rio Grande do Sul, the university hospital (Hospital de Cl-nicas de Porto Alegre, HCPA) and the Children's Cancer Institute (Instituto do C-ncer Infantil do Rio Grande do Sul, ICI-RS) in Porto Alegre, Brazil, have shown that manipulating an epigenetic mechanism, which regulates gene expression, may promote cell death and favor maturation towards less malignant-prone phenotypes in pediatric brain cancer cell lines.

22 Dec 2013

Researchers investigate how androgen receptors affect prostate cancer progression

Approximately 1 out of every 6 American men will be diagnosed with prostate cancer, and this year alone there are expected to be nearly a quarter of a million new cases diagnosed, making prostate cancer the most common malignancy among men in the United States. Center for Nuclear Receptors & Cell Signaling Assistant Professor Daniel Frigo and his research team recently published a study investigating the processes through which androgen receptors affect prostate cancer progression.

22 Dec 2013

New antibody could boost strength, muscle mass in patients with cancer and other diseases

A new antibody could dramatically boost strength and muscle mass in patients with cancer, chronic obstructive pulmonary disease, sporadic inclusion body myositis, and in elderly patients with sarcopenia according to research published ahead of print in the journal Molecular and Cellular Biology.

20 Dec 2013

Experimental drug inhibits BTK molecule in patients with chronic lymphocytic leukemia

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) helps confirm that a molecule targeted by the experimental drug ibrutinib is critical for the development of chronic lymphocytic leukemia, the most common form of adult leukemia.

20 Dec 2013

Researchers map cell's complex genetic interactions to fix UV damaged DNA

Researchers at the University of California, San Diego School of Medicine, with colleagues in The Netherlands and United Kingdom, have produced the first map detailing the network of genetic interactions underlying the cellular response to ultraviolet (UV) radiation.

19 Dec 2013

GSK team wins Drug Discovery of Year award for developing trametinib for malignant melanoma

The British Pharmacological Society proudly announces that its Drug Discovery of the Year award has been won by the team at GlaxoSmithKline (GSK) responsible for the development of trametinib - a new treatment for malignant melanoma (a type of skin cancer).

19 Dec 2013

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

The Ben & Catherine Ivy Foundation today announced a $3 million grant to the Translational Genomics Research Institute (TGen), Nemucore Medical Innovations Inc., and Barrow Neurological Institute at St. Joseph's Hospital and Medical Center to help fund significant brain tumor research in Arizona.

18 Dec 2013

Aerobic glycolysis is a cause of malignancy, show Berkeley Lab researchers

Metabolism was lost in the shadows of cancer research for decades but has recently been reclaiming some of the spotlight. Now, Mina Bissell, Distinguished Scientist with Berkeley Lab's Life Sciences Division and a leading authority on breast cancer, has shown that aerobic glycolysis - glucose metabolism in the presence of oxygen - is not the consequence of the cancerous activity of malignant cells but is itself a cancerous event.

18 Dec 2013

Pelvic radiation therapy to treat uterine cancer may increase risk of developing bladder cancer

Radiation therapy used to treat uterine cancer may increase a patient's risk of developing bladder cancer. That is the conclusion of a recent study published in BJU International.

18 Dec 2013

Cardiovascular disease in asthma needs attention

Researchers say that there should be a greater emphasis on preventing cardiovascular disease in people with asthma after finding that it was the leading cause of death in hospitalized asthma patients.

17 Dec 2013

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

BerGenBio AS, an oncology biopharmaceutical company, announces that preclinical data demonstrating that BGB324 has potential application as a novel treatment for Chronic Myeloid Leukemia, was presented in a poster at the Annual Meeting of the American Society of Hematology, which took place on December 7-10, 2013.

17 Dec 2013

Researchers work on breathalyser device to detect early signs of cancer

Researchers at the University of Huddersfield are working on a breathalyser device that will be able to detect very early signs of cancer, making a cure much more likely.

16 Dec 2013

Chest wall resection effective for recurrent mesothelioma

Salvage chest wall resection could lengthen survival in patients with isolated chest wall recurrence of malignant pleural mesothelioma, research indicates.

16 Dec 2013

Experimental drug that targets macrophages decreases cancer's growth

An experimental drug that targets macrophages, a type of immune cells, in the microenvironment surrounding the lethal brain tumor glioblastoma multiforme decreased the cancer's growth and extended survival of laboratory mice with the cancer, scientists will report on Tuesday Dec. 17, at the American Society for Cell Biology annual meeting in New Orleans.

16 Dec 2013

Standardized research approaches needed for developing new treatments for neurofibromatosis

As potentially effective new treatments for neurofibromatosis (NF) are developed, standardized research approaches—including outcome measures specific to NF—are needed. The first report from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration has been published as a supplement to Neurology, the Official Journal of the American Academy of Neurology (AAN).

13 Dec 2013

Senhwa Biosciences raises additional $17 million USD in Series B financing

Senhwa Biosciences, Inc. has raised an additional $17 million USD in a Series B financing to drive its anticancer agents through critical clinical trials, the company announced today.

12 Dec 2013

Malignant News and Research

Innovative therapy offers new hope to breast cancer patients

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

Concordia Healthcare acquires Pinnacle Biologics

Manipulating epigenetic mechanism may promote cell death in pediatric brain cancer

Researchers investigate how androgen receptors affect prostate cancer progression

New antibody could boost strength, muscle mass in patients with cancer and other diseases

Experimental drug inhibits BTK molecule in patients with chronic lymphocytic leukemia

Researchers map cell's complex genetic interactions to fix UV damaged DNA

GSK team wins Drug Discovery of Year award for developing trametinib for malignant melanoma

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

Aerobic glycolysis is a cause of malignancy, show Berkeley Lab researchers

Pelvic radiation therapy to treat uterine cancer may increase risk of developing bladder cancer

Cardiovascular disease in asthma needs attention

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Researchers work on breathalyser device to detect early signs of cancer

Chest wall resection effective for recurrent mesothelioma

Experimental drug that targets macrophages decreases cancer's growth

Standardized research approaches needed for developing new treatments for neurofibromatosis

Senhwa Biosciences raises additional $17 million USD in Series B financing

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News